R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Tsingke Biotech

Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery

ADC / XDCBiotech

Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab

DiabetesNovo Nordisk

Semaglutide Use Linked to Rare Eye Condition NAION in New Study

AIEli Lilly

Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery

Show More